Erenumab: Enhancing Mood and Sleep in Migraine Relief
- MigraineMind
- Nov 8, 2025
- 1 min read
Research Summary
A recent study published in the European Journal of Neurology examined the effects of erenumab, a monoclonal antibody, on anxiety, depression, and sleep quality in individuals with migraine. Conducted within the Registry for Migraine (REFORM), the study involved 675 adults receiving monthly 140-mg doses of erenumab over 24 weeks. Results showed significant reductions in anxiety and depression risks, as well as improvements in sleep quality among those who responded well to treatment, defined as a 50% or greater reduction in monthly migraine days. These improvements were evident regardless of psychiatric history, suggesting benefits stem from effective migraine control.
Study Details
👥 Research Team: Raffaelli B et al.
📚 Published In: Eur J Neurol
📅 Publication Date: 2025 Nov
⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.